Revenue booming, profit crushed by Philippines ethanol drag

Consolidated revenue up 45% to ₹1,993 Cr; standalone up 51% to ₹1,585 Cr

Manufacturing margins at 12% standalone achieved; consolidated OPM compressed to 6.2% due to ₹83 Cr ethanol loss

Standalone PBT ₹123 Cr (up 10%), but consolidated PAT ₹17.5 Cr (down 70% YoY); profit recovery masked by ethanol drag

Export revenue ₹385 Cr represents 25% of standalone revenue, up from 15% Q1 FY26

Raised from prior 8-9% standalone growth to 10-12% based on stronger order inflows (₹750 Cr+ exports booked in Q1, ₹1,200 Cr booked so far in Jul-Aug FY27) and capex ramp starting Sep 2026.

Reaffirmed 12-13% EBIT margins for manufacturing segment; achieved 12% in Q1 despite geopolitical cost pressures (war-driven material, shipping, logistics). Management indicates contingency buffers are holding.

Moved away from 4-6 year low-margin projects toward 2-2.5 year technology-premium work with focus on exports and higher-margin customer niches; projects margin targeting 5-6% (vs 5.25% in Q1).

Export revenue doubled from 15% of standalone revenue (Q1 FY26) to 25% (Q1 FY27), driven by new orders in Africa, Latin America, Southeast Asia; management targets this level to continue.

Shifted from held-for-sale/discontinued ops to continuing ops in Mar 2026; consolidated PAT now includes full ₹83 Cr loss, restating prior-year Q1 FY26 consolidated results for comparability.

Order book high but much execution carries forward to next financial year; must be realistic about quarterly run-rate. Manufacturing capacity additions progressively online, not immediate. Isgec Hitachi Zosen +10% expected, but Saraswati Sugar down due to poor cane availability.

Phase 1 (₹73 Cr) completes first week September, ₹225 Cr annual revenue potential but builds as work-in-progress; cycle time 8-10 months, so revenue recognized in Q1 FY28. Phase 2 (₹218 Cr) completes end 2027/Q1 2028.

Plant started Dec 2025, ran on cane until Apr 2026 (shorter season than expected), now on molasses feedstock; capacity utilization 65-70%. Expected to improve to much lower losses in Q2 (mostly depreciation + interest); depreciation ₹95 Cr for FY27 (front-loaded ₹37 Cr in Q1 due to WDV method). Reach 90% utilization by December.

Standalone: 4-12 months for manufactured items, 14 months to 2.5 years for projects. Isgec Hitachi Zosen 15-18 months. Pipeline strong across domestic and exports; already booked ₹1,200 Cr in Jul-Aug FY27.

Don't have that number; depends on pricing of cane, molasses, ethanol. Will need to check.

Costs up due to war (materials, logistics, shipping). Carry contingencies; 12-13% target is being met this quarter at 12%. Expect to stay within range; focusing on tech-premium orders and shorter-cycle projects to support margins.

Doing this work before but now segregating to focus attention. Smaller-value orders but higher margins. Hope to double the existing O&M base in 2 years, but no absolute figures given.

Raised from prior 8-9% guidance. Implies ₹8,360-8,580 Cr FY27 revenue on ~₹7,600 Cr FY26 base. Based on ₹750 Cr+ quarterly manufacturing run-rate and ₹1,000 Cr+ projects quarterly with Hitachi Zosen +10%.

From ~₹670 Cr FY26 base, expecting ₹737 Cr FY27. Profits also ~10% higher. Order book ₹889 Cr in hand.

Achieved 12% Q1 FY27. Contingencies in place for geopolitical cost pressures (war-driven material costs, shipping rates, logistics). New capacity from capex expected to support margin range.

Achieved 5.25% Q1 FY27. Targeting improvement through shorter-cycle (2-2.5 year max) and tech-intensive order selection; moving away from 4-6 year low-margin contracts.

Bhartauli machine building ₹70 Cr + ₹218 Cr phases; Dahej SEZ skids/modules; casting factories, tubing/piping, mechanical press expansions. ₹1,200 Cr annual revenue potential when fully complete, largely by 2028-29.

Cavite Biofuel lost ₹83 Cr in Q1 (₹37 Cr depreciation, ₹20 Cr interest, ₹10 Cr forex loss, ₹16 Cr fixed costs). At 65-70% utilization, still running at EBITDA loss. Expected ₹95 Cr depreciation + ₹80 Cr interest for FY27, totaling ₹175 Cr annual drag. Will suppress consolidated profitability through FY28 even if management successfully reaches 90% utilization by Dec 2026.

War has elevated shipping rates, reduced container/ship availability, increased transit times, and raised material costs (steel, copper, aluminium, nickel, energy). Management acknowledges costs absorbed through contingencies this quarter, but margin visibility uncertain if conflict persists. Orders booked today must be executed over 2 years; pricing locked in but cost creep unpredictable.

₹502 Cr capex approved for manufacturing capacity; phase 1 (₹73 Cr, Bhartauli) completes Sep 2026 with ₹225 Cr annual revenue potential but requires 8-10 month production cycle (billing delayed to Q1 FY28). Phase 2 (₹218 Cr) targets end 2027/Q1 2028. Full ₹1,200 Cr benefit largely deferred to 2028-29. If execution slips or demand disappoints, capex returns delayed.

Q1 standalone revenue +51% but PBT only +10% YoY; consolidated PAT -70% YoY. Despite strong revenue execution, higher interest costs (Cavite borrowings ₹20 Cr/quarter), lower other income (forex volatility on Philippines loans), and geopolitical cost pressures are suppressing profit growth. Risk that FY27 margin guidance (12-13% manufacturing) is optimistic if war/logistics costs persist or container spreads widen further.

Order book ₹7,727 Cr (standalone) is robust, but execution timelines span 14 months to 2.5 years. Risk of project delays, cost overruns, or customer disputes if geopolitical disruptions persist. Management shifting to shorter 2-2.5 year cycles and tech-premium work to mitigate, but execution risk remains.